Related Articles
Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer
Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells
Parthenolide suppresses hypoxia-inducible factor-1α signaling and hypoxia induced epithelial-mesenchymal transition in colorectal cancer
Isorhamnetin suppresses colon cancer cell growth through the PI3K‑Akt‑mTOR pathway
Molecular, biological characterization and drug sensitivity of chidamide‑resistant non‑small cell lung cancer cells